Filing Flows › Altimmune (ALT) › Q4 2024
Altimmune (ALT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Altimmune (ALT) reported revenue of $5K for the fourth quarter 2024 (Q4 2024), -86% from a year earlier and 0% from the quarter before.
Altimmune, Q4 2024: revenue $5K (-86% year over year), net loss $23.2M, operating cash flow −$18.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | 0% | -86% |
| Operating profit | −$24.9M | — | — |
| Net earnings | −$23.2M | — | — |
| Operating cash flow | −$18.3M | — | — |
What changed
Revenue was $5K in Q4 2024, down 86% year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $24.9M, an operating margin of -497320.0%. Total costs fell 26% while revenue fell 86%. The fastest-growing cost line was General & admin (+17%). The quarter ended with a net loss of $23.2M, wider than the previous quarter's $22.8M loss.
Operating cash flow was −$18.3M. Non-cash charges added back $33K of depreciation and $3.4M of share-based compensation. Working capital and other items added $1.5M.
Questions
What was Altimmune's revenue in the fourth quarter 2024?
Altimmune (ALT) reported revenue of $5K for the fourth quarter 2024 (Q4 2024), -86% from a year earlier and 0% from the quarter before.
Source: Altimmune 10-K on SEC EDGAR.